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Background:  ACE-inhibitors (ACEI’s) are widely used in patients with lef ventricular dysfunction (LVD) while their efficacy can be negatively affected 
by concomitant administration of ASA with differences among the various compounds.
Methods:  the primary objective of the study was to assess the 1-year combined occurrence of death,CV hospitalization and deterioration of LV 
function (decline in EF% > 15%) in 768 patients with post-MI LVD (CHF and/or EF% < 40%) and randomly allocated to treatment with 30-60 mg/
day of Zofenopril (Z; n.380) or 5-10 mg/day of Ramipril (R; 5-10 mg/day) in combination with ASA (100 mg/day) according to a double-blind study 
design. The effect of trteament on the primary out come was tested in the overall population and in some pre-specified subgroups of patients (DM, 
no prior MI, preserved LV function).
Results: Patients randomized to zofenopril tretament had a more severe baseline risk profile in terms of clinical history (hypertension, prior MI or 
revascularization) and LV function (EF%) while demographic and clinical profile were comparable. Concomitant treatment was comparable both at 
baseline and at the end of follow-up. The primary outcome was non significantly reduced in patients treated with zofenopril vs. ramipril (RR, 95% CI: 
0.80, 0.58-1.12; p=0.19) while the difference in terms of CV hospitalization achieved statistical significance in the same population (RR, 95% CI: 
0.75, 0.41-0.99; p=0.046) after adjustment for the main confounding factors. The primary end-point was significantly reduced in patients without 
prior MI (RR,96% CI:0.67, 0.42-0.91; p=0.01), preserved LV function (RR, 95% CI: 0.63, 0.41-0.94, p=0.044) and diabetes ((RR, 95% CI: 0.61, 0.46-
0.97, p=0.01). Blood pressure control was comparable while a decile in EF > 15% occurred in 24% vs. 35 of Z and R patients respectively (p=0.05).
Conclusions:  The results of the SMILE-IV study support a difference in the efficacy of various ACEI’s when combined with ASA in post-MI patients 
with LV dysfunction. This findings might have important clinical implications for the use of ACEI’s in patients with LVD and heart failure.
